Biomea Fusion (BMEA) Jefferies Global Healthcare Conference 2026 summary

Strategic focus and pipeline overview

• Shifted focus to metabolic diseases, specifically diabetes and obesity, after identifying menin as a key protein target for metabolic regulation.

• Advanced two main programs: menin inhibition for diabetes and a small molecule oral GLP-1 for obesity, both progressing through clinical trials.

• Phase II studies (COVALENT-211 and COVALENT-212) target insulin-deficient and GLP-1-treated populations, with readouts expected in the next 12 months.

• Early clinical data show promising results in both Type 1 and Type 2 diabetes, as well as obesity.

Menin inhibitor clinical development and regulatory alignment

• Menin inhibition aims to restore beta cell function, potentially offering a non-chronic, restorative diabetes treatment.

• FDA has agreed to non-chronic dosing and primary endpoints at six months off-drug, with secondary endpoints at 12 months.

• Enrollment criteria focus on insulin-deficient adults with high A1C who have failed one to three prior agents, and GLP-1-treated patients with uncontrolled A1C.

• Regulatory discussions indicate openness to novel, non-chronic approaches, with study designs and endpoints aligned with FDA expectations.

Market potential, pricing, and payer considerations

• One-time or short-term treatment could reduce long-term diabetes complications and associated healthcare costs.

• Estimated cost savings of $30,000+ per year if insulin use is delayed, with potential pricing between $8,000 and $12,000 per course.

• Pricing strategy will balance broad patient access and value creation, with adjustments possible based on duration of benefit.